Abstract: Disclosed examples relate to a power conversion system configured to provide a power output from an arrangement of direct current (DC) power sources. One example power conversion system includes multiple power sources PV(n), n=1 to x, connected in a series. For each power source PV(n) for n=1 to x?1, the power conversion system includes an intermediate bidirectional voltage converter VC(n) connected to a first terminal of the power source PV(n), a first terminal of power source PV(x), and a second terminal of power source PV(1). Each intermediate bidirectional voltage converter VC(n) includes a first switch operable in a pulsed mode to boost a power output by power source PV(n) and a second switch operable in a pulsed mode to reduce a power output by power source PV(n). The power conversion system also includes a balancer VC(x) connected to the first terminal of PV(x) and to a load.

Abstract: The present disclosure relates to identifying azimuth error and determining an azimuth of an antenna installed in a cell of a cellular network. In a preferred embodiment, the network entity receives a plurality of transmission parameters basis to which the network entity identifies a target cell. The network entity further divides angular region of the cell serving the target cell into a plurality of cones out of which a target cone is identified by the network entity. The network entity then performs first iteration yielding a first azimuth, and in an event of an azimuth error in the first azimuth, the network entity performs second iteration yielding a second azimuth. The present disclosure also encompasses predicting an optimum azimuth of said antenna in an event of azimuth error/s in the first azimuth and the second azimuth.

Abstract: Systems and methods are provided for maintaining charge control of a battery array where a plurality of batteries is serially connected. Each of the battery has an odd switch and an even switch. A battery charge current and voltage for each of the battery is controlled by establishing a controlled charging for the batteries. The odd switch is controlled using a Pulse Width Modulation (PWM) signal. An inductor coupled with the battery array supplies stored power to each of the battery of the plurality of batteries. The battery charge current and voltage is managed by either establishing a restricted battery charge current or battery voltage for one of the battery with high SOC or the battery that is to be charged with lower current rate is switched by a lower duty cycle PWM signal while the remaining batteries are charged with a higher duty cycle PWM signal.

Abstract: The present disclosure relates to identifying azimuth error and determining an azimuth of an antenna installed in a cell of a cellular network. In a preferred embodiment, the network entity receives a plurality of transmission parameters basis to which the network entity identifies a target cell. The network entity further divides angular region of the cell serving the target cell into a plurality of cones out of which a target cone is identified by the network entity. The network entity then performs first iteration yielding a first azimuth, and in an event of an azimuth error in the first azimuth, the network entity performs second iteration yielding a second azimuth. The present disclosure also encompasses predicting an optimum azimuth of said antenna in an event of azimuth error/s in the first azimuth and the second azimuth.

Abstract: Disclosed examples relate to a power conversion system configured to provide a power output from an arrangement of direct current (DC) power sources. One example power conversion system includes multiple power sources PV(n), n=1 to x, connected in a series. For each power source PV(n) for n=1 to x?1, the power conversion system includes an intermediate bidirectional voltage converter VC(n) connected to a first terminal of the power source PV(n), a first terminal of power source PV(x), and a second terminal of power source PV(1). Each intermediate bidirectional voltage converter VC(n) includes a first switch operable in a pulsed mode to boost a power output by power source PV(n) and a second switch operable in a pulsed mode to reduce a power output by power source PV(n). The power conversion system also includes a balancer VC(x) connected to the first terminal of PV(x) and to a load.

Abstract: The present invention provides process for preparation of Crystalline Erlotinib HCl (I) Form-SE characterized by X-ray powder diffraction pattern comprising at least 5 characteristic 2?° peaks selected from the XRPD peak set of 5.60, 10.00, 11.40, 13.00, 13.50, 15.20, 18.40, 20.65, 21.86, 23.5, 31.80, 32.13, 32.80, 34.40±0.20 2?°, DSC isotherm comprising the endothermic peaks ranging between 213 to 217° C. (Peak ?1) and 225 to 235° C. (Peak ?2) and IR absorption characteristic peaks at approximately 3278 cm?1, 1948 cm?1, 1871 cm?1, 1632 cm?1, 1164 cm?1, 1024 cm?1, 940 cm?1 and 742 cm?1 useful as active pharmaceutical ingredient in pharmaceutical compositions for the treatment cancer.

Abstract: The present invention provides a non-solvated amorphous form of (2?,5?,7?,10?,13?)-4-acetoxy-13-({(2R,3S)-3[ (tert-butoxy carbonyl) amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate or Cabazitaxel (I), and process for preparation thereof. The present application also provides a non-solvated amorphous form of (2?,5?,7?,10?,13?)-4-acetoxy-13-({(2R,3S)-3[ (tert-butoxy carbonyl) amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate or Cabazitaxel (I) having an XRPD pattern as per FIG. 1, and IR spectrum as per FIG. 3 and is useful as an active pharmaceutical in a pharmaceutical composition comprising thereof and has anti-cancer activity.

Abstract: The present invention relates to crystalline 2-Chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide (I) designated as Form-SV and process for preparation thereof. The invention further relates to pharmaceutical compositions comprising crystalline Form-SV or non-crystalline form of (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide, useful in the treatment of cancer.

Abstract: The present invention relates to crystalline 2-Chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide (I) designated as Form-SV and process for preparation thereof. The invention further relates to pharmaceutical compositions comprising crystalline Form-SV or non-crystalline form of (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide, useful in the treatment of cancer.

Abstract: The present invention provides crystalline polymorphic forms of Fingolimod HCl (I) and processes for preparation thereof. The application provides processes for preparation of crystalline polymorphic forms-?, ? and ? substantially free from process related impurities. The crystalline polymorphic forms of Fingolimod HCl (I) obtained by the processes according to the present invention having an XRDP pattern as per FIGS. 1, 3 and 5, which are useful as active pharmaceutical ingredient in pharmaceutical compositions for the treatment or prevention of autoimmune related disorder including multiple sclerosis.

Abstract: The present invention provides process for preparation of crystalline Bortezomib (Ia) as its monohydrate which is designated as crystalline Form-SB and characterized by having water content ranging between 3.5-6.0% w/w; X-ray powder diffraction pattern comprising characteristic 2?° peaks selected from the XRPD peak set of 5.6, 7.5, 9.8, 10.2, 11.3, 15.1, 18.0, 20.5, 21.5 and 23.6±0.20 2?°, wherein peaks at 9.8 and 11.39±0.20 2?° are un-split and 100% intensity peak is present at 5.6±0.20 2?°, DSC isotherm comprising the endothermic peaks ranging between 45 to 60° C. (Peak-1) and 175 to 185° C. (Peak-2) and IR absorption characteristic peaks approximately at 3387 cm?1, 3304 cm?1, 2953 cm?1, 2927 cm?1, 2868 cm?1, 1627 cm?1, 1455 cm?1, 1400 cm?1, 1201 cm?1, 1150 cm?1, 1020 cm?1, 747 cm?1 and 702 cm?1 and Raman absorption spectra having characteristic peaks approximately at 3066 cm?1, 1583 cm?1, 1528 cm?1, 1281 cm?1, 1213 cm?1, 1035 cm?1, 1022 cm?1 and 1004 cm?1.

Abstract: The present invention provides process for preparation of Crystalline Erlotinib HCl (I) Form-SE characterized by X-ray powder diffraction pattern comprising at least 5 characteristic 2?° peaks selected from the XRPD peak set of 5.60, 10.00, 11.40, 13.00, 13.50, 15.20, 18.40, 20.65, 21.86, 23.5, 31.80, 32.13, 32.80, 34.40±0.20 2?°, DSC isotherm comprising the endothermic peaks ranging between 213 to 217° C. (Peak -1) and 225 to 235° C. (Peak -2) and IR absorption characteristic peaks at approximately 3278 cm?1, 1948 cm?1, 1871 cm?1, 1632 cm?1, 1164 cm?1, 1024 cm?1, 940 cm?1 and 742 cm?1 useful as active pharmaceutical ingredient in pharmaceutical compositions for the treatment cancer.

Abstract: The present invention provides Di potassium (S)-2-(4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzamido)pentanedioate (I) and its hydrates useful as active pharmaceutical ingredient in pharmaceutical compositions for the treatment of cancer. The present invention also provides process for preparation thereof.

Abstract: The present invention provide processes for the preparation of highly pure Bendamustine hydrochloride monohydrate of formula (I) The present application relates to Bendamustine hydrochloride monohydrate crystalline Form-SM characterized by X-ray powder diffraction pattern as depicted in FIG. 1 consisting peaks selected from the XRPD 2 theta degrees peaks at 7.42, 10.60, 11.17, 16.43, 17.94, 22.89, 26.33, 28.77, 30.28, 31.92, and 40.89±0.1 2?° having a purity of greater than 99.5% (by HPLC). The present application also provides a process for the preparation of highly pure Bendamustine hydrochloride monohydrate crystalline Form-SM useful in making pharmaceutical composition for the treatment of cancer or similar proliferative disorders.

Abstract: The present invention provides a non-solvated amorphous form of (2?,5?,7?,10?,13?)-4-acetoxy-13-({(2R,3S)-3[ (tert-butoxy carbonyl) amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate or Cabazitaxel (I), and process for preparation thereof. The present application also provides a non-solvated amorphous form of (2?,5?,7?,10?,13?)-4-acetoxy-13-({(2R,3S)-3[ (tert-butoxy carbonyl) amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate or Cabazitaxel (I) having an XRPD pattern as per FIG. 1, and IR spectrum as per FIG. 3 and is useful as an active pharmaceutical in a pharmaceutical composition comprising thereof and has anti-cancer activity.

Abstract: The present invention provides crystalline polymorphic forms of Fingolimod HCl (I) and processes for preparation thereof. The application provides processes for preparation of crystalline polymorphic forms-?, ? and ? substantially free from process related impurities. The crystalline polymorphic forms of Fingolimod HCl (I) obtained by the processes according to the present invention having an XRDP pattern as per FIGS. 1, 3 and 5, which are useful as active pharmaceutical ingredient in pharmaceutical compositions for the treatment or prevention of autoimmune related disorder including multiple sclerosis.

Abstract: The present invention provide processes for the preparation of Bendamustine hydrochloride monohydrate of formula (I) The present application also provides a process of purification of Bendamustine hydrochloride or monohydrate to get substantially pure Bendamustine hydrochloride monohydrate crystalline Form-SM. The said Bendamustine hydrochloride monohydrate crystalline Form-SM is characterized by X-ray powder diffraction pattern comprising at least 5 characteristic peaks selected from the XRPD 2 theta degrees peaks at 7.42, 10.60, 11.17, 16.43, 17.94, 22.89, 26.33, 28.77, 30.28, 31.92, 40.89±0.1 2?°. The present application also provides a process for the preparation of Bendamustine hydrochloride monohydrate crystalline Form-SM useful in making pharmaceutical composition for the treatment of cancer or similar proliferative disorders.

Abstract: The present invention relates to novel heterocyclic diphenyl ether and diphenyl amine compounds, derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and pharmaceutically acceptable solvates thereof and pharmaceutically acceptable compositions containing these singly or in combination. The compounds of the present invention are effective in lowering blood glucose, serum insulin, free fatty acids, cholesterol and triglyceride levels and are useful in the treatment and/or prophylaxis of diabetes. The compounds of the present invention are effective in treatment of obesity, inflammation, autoimmune diseases such as multiple sclerosis and rheumatoid arthritis and immunological diseases, including the treatment of cancer. Furthermore, the compounds are useful for the treatment of disorders associated with insulin resistance.

Abstract: This invention relates to a novel class of acidic amino acid/dicarboxylic acid derivatives (sulfonic acid/sulfate derivatives of naturally occurring amino acids and their amides) useful as inhibitors of osteoclastogenesis. The invention also provides methods of using the novel class of acidic amino acid/dicarboxylic acid derivatives of the general formula ZOC—(CRR)m—COOH, wherein: m=2, 3 or 4; Z is OH or NH2; one R in the compound is from the group consisting of SO3H, OSO3H, CH2—SO3H, CH2—OSO3H, and NHSO3H, and the remaining Rs are H or NH2, for inhibition of osteoclastogenesis.

Abstract: An electrically powered vehicle includes an inverter mounted in the vehicle, the inverter having a plurality of high power IGBT modules for converting DC power to AC power for application to a plurality of AC electric motors connected in driving relationship to wheels on the vehicle. Each of the IGBT modules is mounted in thermal transfer relationship to an electrically isolated base plate and each base plate has a plurality of closely spaced, parallel slots formed across one surface with a plurality of fins fitted into the slots and extending from the base plate. The system includes apparatus for mounting the IGBT modules to a wall separating an electronics compartment from an air supply and air exhaust compartment. Air from an air supply plenum in the air supply compartment is directed into the fins extending from the IGBT base plate and exhaust through an exhaust conduit. The vehicle includes a blower to force air to flow through the fins extending from the base plate.